Temporal pattern of ICAM-I mediated regulatory T cell recruitment to sites of inflammation in adoptive transfer model of multiple sclerosis

PLoS ONE

Volumn 5, Issue 11, 2010, Pages

  Doerck, Sebastian ^a   Göbel, Kerstin ^b   Weise, Gesa ^a   Schneider Hohendorf, Tilman ^b   Reinhardt, Michael ^c   Hauff, Peter ^c   Schwab, Nicholas ^b   Linker, Ralf ^d   Mäurer, Mathias ^e   Meuth, Sven G ^a,b,f   Wiend, Heinz ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c BAYER PHARMA AG   (Germany)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e CARITAS KRANKENHAUS   (Germany)

^f Institute of Physiology I Neuropathophysiology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; TRANSCRIPTION FACTOR FOXP3; VASCULAR CELL ADHESION MOLECULE 1;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COMPOSITION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; IN VIVO STUDY; INFLAMMATION; LYMPHOCYTE COUNT; LYMPHOCYTE MIGRATION; LYMPHOCYTIC INFILTRATION; MOLECULAR DYNAMICS; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; NONHUMAN; ONSET AGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; REGULATORY T LYMPHOCYTE; REMISSION; UPREGULATION; ALLERGIC ENCEPHALOMYELITIS; ANIMAL; DISEASE MODEL; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LEWIS RAT; METABOLISM; PATHOLOGY; TIME;

ANIMALIA; RATTUS;

ADOPTIVE TRANSFER; ANIMALS; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR ADHESION MOLECULE-1; MULTIPLE SCLEROSIS; RATS; RATS, INBRED LEW; T-LYMPHOCYTES, REGULATORY; TIME FACTORS; VASCULAR CELL ADHESION MOLECULE-1;

EID: 78649746018     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015478     Document Type: Article

References (41)

1. Tang Q, Bluestone JA (2008) The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol 9: 239-244.
2. Morgan ME, Sutmuller RP, Witteveen HJ, van Duivenvoorde LM, Zanelli E, et al. (2003) CD25+ cell depletion hastens the onset of severe disease in collageninduced arthritis. Arthritis Rheum 48: 1452-1460.
3. Kohm AP, Carpentier PA, Anger HA, Miller SD (2002) Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J Immunol 169: 4712-4716.
4. Korn T, Reddy J, Gao W, Bettelli E, Awasthi A, et al. (2007) Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat Med 13: 423-431.
5. Herman AE, Freeman GJ, Mathis D, Benoist C (2004) CD4+CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion. J Exp Med 199: 1479-1489.
6. Piccirillo CA, Tritt M, Sgouroudis E, Albanese A, Pyzik M, et al. (2005) Control of type 1 autoimmune diabetes by naturally occurring CD4+CD25+ regulatory T lymphocytes in neonatal NOD mice. Ann N Y Acad Sci 1051: 72-87.
7. Zozulya AL, Wiendl H (2008) The role of regulatory T cells in multiple sclerosis. Nat Clin Pract Neurol 4: 384-398.
8. Takahashi T, Kuniyasu Y, Toda M, Sakaguchi N, Itoh M, et al. (1998) Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/ suppressive state. Int Immunol 10: 1969-1980
9. Sakaguchi S (2004) Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22: 531-562.
10. Lee JH, Kang SG, Kim CH (2007) FoxP3+ T cells undergo conventional first switch to lymphoid tissue homing receptors in thymus but accelerated second switch to nonlymphoid tissue homing receptors in secondary lymphoid tissues. J Immunol 178: 301-311.
11. O'Connor RA, Malpass KH, Anderton SM (2007) The inflamed central nervous system drives the activation and rapid proliferation of Foxp3+ regulatory T cells. J Immunol 179: 958-966.
12. Gartner D, Hoff H, Gimsa U, Burmester GR, Brunner-Weinzierl MC (2006) CD25 regulatory T cells determine secondary but not primary remission in EAE: impact on long-term disease progression. J Neuroimmunol 172: 73-84.
13. Man S, Ubogu EE, Ransohoff RM (2007) Inflammatory cell migration into the central nervous system: a few new twists on an old tale. Brain Pathol 17: 243-250.
14. Engelhardt B (2006) Molecular mechanisms involved in T cell migration across the blood-brain barrier. J Neural Transm 113: 477-485.
15. Abbott NJ, Patabendige AA, Dolman DEM, Yusof SR, Begley DJ (2010) Structure and function of the blood-brain barrier. Neurobiol Dis 37: 13-25.
16. Archelos JJ, Previtali SC, Hartung HP (1999) The role of integrins in immunemediated diseases of the nervous system. Trends Neurosci 22: 30-38.
17. Engelhardt B, Laschinger M, Schulz M, Samulowitz U, Vestweber D, et al. (1998) The development of experimental autoimmune encephalomyelitis in the mouse requires alpha4-integrin but not alpha4beta7-integrin. J Clin Invest 102: 2096-2105.
18. Engelhardt B (2003) Development of the blood-brain barrier. Cell Tissue Res 314: 119-129.
19. Laschinger M, Vajkoczy P, Engelhardt B (2002) Encephalitogenic T cells use LFA-1 for transendothelial migration but not during capture and initial adhesion strengthening in healthy spinal cord microvessels in vivo. Eur J Immunol 32: 3598-3606.
20. Engelhardt B (1998) The role of alpha 4-integrin in T lymphocyte migration into the inflamed and noninflamed central nervous system. Curr Top Microbiol mmunol 231: 51-64.
21. Vajkoczy P, Laschinger M, Engelhardt B (2001) Alpha4-integrin-VCAM-1 binding mediates G protein-independent capture of encephalitogenic T cell blasts to CNS white matter microvessels. J Clin Invest 108: 557-565.
22. Gold R, Hartung HP, Toyka KV (2000) Animal models for autoimmune demyelinating disorders of the nervous system. Mol Med Today 6: 88-91.
23. Gold R, Linington C, Lassmann H (2006) Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129: 1953-1971.
24. Linker RA, Reinhardt M, Bendszus M, Ladewig G, Briel A, et al. (2005) In vivo molecular imaging of adhesion molecules in experimental autoimmune encephalomyelitis (EAE). J Autoimmun 25: 199-205.
25. Reinhardt M, Hauff P, Briel A, Uhlendorf V, Linker RA, et al. (2005) Sensitive particle acoustic quantification (SPAQ): a new ultrasound-based approach for the quantification of ultrasound contrast media in high concentrations. Invest Radiol 40: 2-7.
26. Linker RA, Maurer M, Gaupp S, Martini R, Holtmann B, et al. (2002) CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation. Nat Med 8: 620-624.
27. Magnus T, Schreiner B, Korn T, Jack C, Guo H, et al. (2005) Microglial expression of the B7 family member B7 homolog 1 confers strong immune inhibition: implications for immune responses and autoimmunity in the CNS. J Neurosci 25: 2537-2546.
28. Beyersdorf N, Gaupp S, Balbach K, Schmidt J, Toyka KV, et al. (2005) Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J Exp Med 202: 445-455.
29. Bluestone JA, Tang Q (2005) How do CD4+CD25+ regulatory T cells control autoimmunity? Curr Opin Immunol 17: 638-642.
30. McGeachy MJ, Stephens LA, Anderton SM (2005) Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4+CD25+ regulatory cells within the central nervous system. J Immunol 175: 3025-3032.
31. Huang YH, Zozulya AL, Weidenfeller C, Metz I, Buck D, et al. (2009) Specific central nervous system recruitment of HLA-G(+) regulatory T cells in multiple sclerosis. Ann Neurol 66: 171-183.
32. Feger U, Luther C, Poeschel S, Melms A, Tolosa E, et al. (2007) Increased frequency of CD4+ CD25+ regulatory T cells in the cerebrospinal fluid but not in the blood of multiple sclerosis patients. Clin Exp Immunol 147: 412-418.
33. Correale J, Villa A (2010) Role of CD8+ CD25+ Foxp3+ regulatory T cells in multiple sclerosis. Ann Neurol 67: 625-638.
34. Tischner D, Weishaupt A, van den Brandt J, Muller N, Beyersdorf N, et al. (2006) Polyclonal expansion of regulatory T cells interferes with effector cell migration in a model of multiple sclerosis. Brain 129: 2635-2647.
35. Hiura T, Kagamu H, Miura S, Ishida A, Tanaka H, et al. (2005) Both regulatory T cells and antitumor effector T cells are primed in the same draining lymph nodes during tumor progression. J Immunol 175: 5058-5066.
36. Morrissey SP, Deichmann R, Syha J, Simonis C, Zettl U, et al. (1996) Partial inhibition of AT-EAE by an antibody to ICAM-1: clinico-histological and MRI studies. J Neuroimmunol 69: 85-93.
37. Archelos JJ, Jung S, Maurer M, Schmied M, Lassmann H, et al. (1993) Inhibition of experimental autoimmune encephalomyelitis by an antibody to the intercellular adhesion molecule ICAM-1. Ann Neurol 34: 145-154.
38. Rose JW, Welsh CT, Hill KE, Houtchens MK, Fujinami RS, et al. (1999) Contrasting effects of anti-adhesion molecule therapy in experimental allergic encephalomyelitis and Theiler's murine encephalomyelitis. J Neuroimmunol 97: 110-118.
39. Willenborg DO, Simmons RD, Tamatani T, Miyasaka M (1993) ICAM-1- dependent pathway is not critically involved in the inflammatory process of autoimmune encephalomyelitis or in cytokine-induced inflammation of the central nervous system. J Neuroimmunol 45: 147-154.
40. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, et al. (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. NEngl J Med 354: 911-923.
41. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, et al. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354: 899-910.